For research use only. Not for therapeutic Use.
VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM) with an IC50 of 347 nM[1].
VU6012962 is highly selective for mGlu7 versus the other seven mGlu receptor subtypes[1].
VU6012962 (1-10 mg/kg; i.p. injection; 60 minutes prior to testing) decreases anxiety in the elevated zero maze (EZM) assay in mice[1].
| Catalog Number | I019463 |
| CAS Number | 2313526-86-0 |
| Synonyms | 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]benzamide |
| Molecular Formula | C21H19F3N4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H19F3N4O4/c1-30-19-8-14(4-7-18(19)31-10-13-2-3-13)20(29)27-16-9-15(32-21(22,23)24)5-6-17(16)28-12-25-11-26-28/h4-9,11-13H,2-3,10H2,1H3,(H,27,29) |
| InChIKey | IQNLJJLZIVCGFI-UHFFFAOYSA-N |
| SMILES | COC1=C(C=CC(=C1)C(=O)NC2=C(C=CC(=C2)OC(F)(F)F)N3C=NC=N3)OCC4CC4 |
| Reference | [1]. Reed CW, et al. Discovery of an orally bioavailable and Central Nervous System (CNS) penetrant mGlu7 NegativeAllosteric Modulator (NAM) in vivo tool compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). J Med Chem. 2019 Jan 4. |
